NCT02572778 Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
| NCT ID | NCT02572778 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
| Condition | Squamous Cell Carcinoma of the Head and Neck |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2015-09 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2015-09 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models
Eligibility Criteria
Inclusion Criteria: * In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent * Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available * Follow-up data should be available * Patients with recurrent disease are allowed * Written informed consent
Contact & Investigator
Jean-Pascal Machiels, MD, PhD
PRINCIPAL INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Frequently Asked Questions
Who can join the NCT02572778 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Squamous Cell Carcinoma of the Head and Neck. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02572778 currently recruiting?
Yes, NCT02572778 is actively recruiting participants. Contact the research team at aline.gillain@uclouvain.be for enrollment information.
Where is the NCT02572778 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT02572778 clinical trial?
NCT02572778 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The principal investigator is Jean-Pascal Machiels, MD, PhD at Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The trial plans to enroll 40 participants.